Analyst Price Target Update on NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA): 11 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $60.36 in NuVasive (NASDAQ:NUVA). However, the stock price could fluctuate by $ 3.83 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $68 price target with the lower price estimate is calculated at $56

Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Barclays, upgrades their rating on the shares of NuVasive (NASDAQ:NUVA). Barclays has a Overweight rating on the shares. Previously, the analysts had a Equal-weight rating on the shares. As per the latest research report, the brokerage house raises the price target to $63 per share from a prior target of $58. The rating by the firm was issued on May 27, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, Miles Patrick, officer (President and COO) of Nuvasive Inc, unloaded 10,723 shares at an average price of $54.41 on January 6, 2016. The total amount of the transaction was worth $583,438, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

NuVasive (NASDAQ:NUVA) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.75 points or 1.27% at $58.23 with 912,518 shares getting traded. Post opening the session at $59.03, the shares hit an intraday low of $58.1 and an intraday high of $59.43 and the price was in this range throughout the day. The company has a market cap of $2,902 million and the number of outstanding shares have been calculated to be 49,833,030 shares. The 52-week high of NuVasive (NASDAQ:NUVA) is $60.09 and the 52-week low is $36.81.

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.